These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20452541)

  • 1. Is losartan the true panacea for aneurysm disease? PRO.
    Collins MJ; Elefteriades JA
    Cardiol Clin; 2010 May; 28(2):273-7. PubMed ID: 20452541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is losartan the true panacea for aneurysm disease? CON.
    Danyi P; Jovin IS
    Cardiol Clin; 2010 May; 28(2):279-85. PubMed ID: 20452542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.
    Moltzer E; Essers J; van Esch JH; Roos-Hesselink JW; Danser AH
    Pharmacol Ther; 2011 Jul; 131(1):50-60. PubMed ID: 21504760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin reduces Marfan aortic dilation.
    McLoughlin D; McGuinness J; Byrne J; Terzo E; Huuskonen V; McAllister H; Black A; Kearney S; Kay E; Hill AD; Dietz HC; Redmond JM
    Circulation; 2011 Sep; 124(11 Suppl):S168-73. PubMed ID: 21911808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights in the pathogenesis of aortic aneurysms.
    Loeys B; De Paepe A
    Verh K Acad Geneeskd Belg; 2008; 70(2):69-84. PubMed ID: 18630721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
    Plante E; Lachance D; Beaudoin J; Champetier S; Roussel E; Arsenault M; Couet J
    Circ Heart Fail; 2009 Jan; 2(1):25-32. PubMed ID: 19808312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
    Hofmann Bowman MA; Eagle KA; Milewicz DM
    JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats.
    Gunduz Z; Dursun N; Akgun H; Ozturk F; Okur H; Koc N
    Regul Pept; 2005 Dec; 132(1-3):59-66. PubMed ID: 16229907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comment: losartan-based medical therapy for aneurysm disease.
    Elefteriades JA
    Cardiol Clin; 2010 May; 28(2):287-8. PubMed ID: 20452543
    [No Abstract]   [Full Text] [Related]  

  • 11. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
    Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
    Mallat Z; Daugherty A
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
    Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
    Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
    Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could medical intervention work for aortic aneurysms?
    Baxter BT
    Am J Surg; 2004 Dec; 188(6):628-32. PubMed ID: 15619475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.